|
|
 |
|
Viewing report
|
|
|
|
Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, Sep 2011, Pages: 78
Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ALL market. The report identifies the key trends shaping and driving the global ALL market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ALL sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates the major markets (the US, the UK, Italy, Spain, France, Germany and Japan) for acute lymphocytic leukemia (ALL) therapeutics was valued at $427.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 2.9% to reach $524.0m by 2017. This growth is primarily attributed to the expected launch of Phase III pipeline candidates Marqibo (vincristine sulfate liposomes injection), GRASPA (asparaginase loaded into erythrocytes), recombinant asparaginase (asparaginase) and Depocyt (liposomal cytarabine) during the forecast period. The moderate growth rate is primarily attributed to the patent expiry of Gleevec in 2015 in the US; 2016 in Europe, Clolar in 2015 in Europe and Arranon in 2017 in US; 2013 in Europe.
Scope
The report provides information on the key drivers and challenges of the acute lymphocytic leukemia market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ALL therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as tyrosine kinase inhibitor, DNA polymerase inhibitor, histone deacetylase (HDAC) inhibitor, dihydrofolate reductase inhibitor and Eg5 Inhibitor.
- Analysis of the current and future competition in the seven key countries ALL therapeutics market. Key market players covered are Talon Therapeutics, Inc., Pfizer Inc, Genzyme Corporation, Erytech Pharma and Micromet, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ALL therapeutics market.
- Analysis of key recent licensing and partnership agreements in ALL therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ALL therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute lymphocytic leukemia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ALL therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
